Revive Therapeutics Ltd. is a listed company. Its directors and officers file their transactions with SEDI. The last twelve months, up to 18 October 2026, brought 8 filings signed by 6 insiders.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
No insider has bought Revive Therapeutics Ltd. shares on the open market in the past twelve months. The median gap between a trade and its publication by SEDI is 3 days. That lag is the time during which only the insider knows about the trade.
With 8 filings in twelve months, the company is quieter than the median of 12 filings across the 2,144 companies we follow on the same exchange.
This summary is built from SEDI disclosures alone and does not predict where the share price will go.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
· cache
8 of 8 declarations
Revive Therapeutics Ltd. is a company focused on developing innovative therapeutic treatments. It is listed on the XTSE market.